Abstract| Volume 23, ISSUE 3, PB4, March 2022

Anxiolytic Drugs for Anxiety: Adverse Effects May Be Worse Than the Mood Disorder. A Case of Buspirone Induced Facial Dyskinesia

      Dopamine, a neurotransmitter for motor function, is implicated in dyskinetic illness. Movement disorders are significant adverse drug effects (ADEs) of several psychotropic drugs with anti-dopamine action. Buspirone, an azapirone, is a partial agonist to serotonin 5HT1A. The medication's therapeutic advantages relate to its interaction with these receptors. Buspirone also inhibits dopamine receptors, which could be linked to the medication's unusual side effects in individuals who are predisposed to them.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect